Alexandre Trifilieff
Editor

2014

The First Once-daily Long-acting Beta2
Agonist for COPD

Chronic obstructive pulmonary disease (COPD) is a multicomponent disease (including emphysema and chronic bronchitis which may or may not coexist in the same individual) leading to a disease state characterized by poorly reversible airflow limitation that is usually progressive and associated with an abnormal inflammatory response of the lung. This disease constitutes a major public health burden worldwide, and the World Health Organization estimates COPD to be the world’s fifth most common disease and fourth leading cause of death.